Who Paid My Doc
Chika Anekwe
Obesity Medicine Boston, MA Medical Doctor
NPI 1487945267 CMS profile 633262
50 Staniford St Fl 4, Boston, MA 02114
General payments
$6,882
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Chika Anekwe of Boston, MA is reported in the CMS Open Payments database as having received $6,882 across 19 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,400 | 12 | |
| 2024 | General | $72 | 2 | |
| 2023 | General | $279 | 3 | |
| 2019 | General | $131 | 2 |
Beside peers
- Chika Anekwe
- Obesity Medicine median
- Middle half of Obesity Medicine
- National median
In program year 2025, general payments to Chika Anekwe were reported at $6,400. Among 30 Obesity Medicine profiles paid that year, the median was $190 and the middle half received between $125 and $2,258.
Show as a table
| Year | Chika Anekwe | Obesity Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $131 | $128 | $31–$684 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $140 | $105–$307 | $132 |
| 2022 | $0 | $94 | $36–$376 | $149 |
| 2023 | $279 | $118 | $44–$1,006 | $160 |
| 2024 | $72 | $122 | $75–$730 | $164 |
| 2025 | $6,400 | $190 | $125–$2,258 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
600
Drug cost
$558,119
Branded share of claims
73.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Wegovy Semaglutide | Brand | 120 | $186,144 | |
| Mounjaro Tirzepatide | Brand | 134 | $167,971 | |
| Ozempic Semaglutide | Brand | 98 | $152,272 | |
| Trulicity Dulaglutide | Brand | 24 | $36,226 | |
| Rybelsus Semaglutide | Brand | 12 | $11,654 | |
| Bupropion Xl Bupropion Hcl | Brand | 32 | $1,256 | |
| Naltrexone Hcl | Generic | 35 | $879 | |
| Topiramate | Generic | 65 | $717 | |
| Metformin Hcl | Generic | 60 | $537 | |
| Metformin Hcl Er Metformin Hcl | Brand | 20 | $462 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 584 Part D prescribers listed as Preventive Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$24,262
Medicare patients
154
Services billed
223
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 51% | |
| Depression | 41% | |
| Diabetes | 34% | |
| Ischemic heart disease | 21% | |
| Cancer | 19% | |
| Chronic kidney disease | 18% | |
| Atrial fibrillation | 12% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obesity Medicine in Massachusetts
Related records
Obesity Medicine in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Obesity Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.